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Abstract
Pulmonary arterial hypertension (PAH) is a debilitating disease characterized by constriction in the diameter of the pulmonary arterial lumen.1·2 This leads to increased pressure
and stress on the right ventricle of the heart, which may lead
to heart failure and deathP Currently there are only a few
treatment options for patients with PAH. Sildenafil, a phosphodiesterase type 5 (PDE-5) inhibitor, can be used to treat
PAH. Sildenafil inhibits the degradation of cyclic guanosine
monophosphate (cGMP). Increased cGMP concentration re'sults in pulmonary vasculature relaxation. Current clinical
,trials have indicated that sildenafil can significantly improve
.many of the symptoms of PAH. The trials have also shown
·that when used appropriately, sildenafil can be used with
minimal side effects. It is important for pharmacists and
:other health care professionals to understand PAH as a dis:ease state and its treatment options, such as sildenafil.
Introduction
Pulmonary arterial hypertension (PAH) is a debilitating disease that, if left untreated, will lead to death. 1 Pulmonary
arterial hypertension is characterized by constriction in the
diameter of the pulmonary arterial lumen.2 Since there is less
space for blood to pass through, pressure begins to build up
in the pulmonary artery. As a result, stress is exerted on the
right side of the heart which can lead to heart failure and
death. Due to its low prevalence, health care practitioners
only have a few options for treating PAH: prostacyclins and
prostacyclin analogues which cause dilation of blood vessels
and a decrease in platelet adhesion, endothelin receptor antagonists which prevent endothelin from constricting blood
vessels or PDE-5 inhibitors which lead to vasodilation.2.3.4
Other medications are typically used in conjunction with
these options, such as diuretics, digoxin, calcium channel
blockers and anticoagulants.4
In their more widely advertised role, PDE-5 inhibitors are
indicated to treat erectile dysfunction through their vasodilation activity. Sildenafil, under the brand name of Viagra®, is a
PDE-5 inhibitor currently indicated to treat erectile dysfunction.s Under the brand name Revatio®, sildenafil is indicated
for PAH as well. It is important to note that in November
2012, generic versions of sildenafil became available to the
public. The intent of using sildenafil in PAH patients is to dilate the pulmonary artery and ultimately relieve some of the
stress on the heart. 1 Current studies have indicated that sildenafil is an effective treatment for PAH. Through a review
of current literature, the writers hope to review the presentation and dangers of PAH and describe when sildenafil
monotherapy is an appropriate treatment.
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Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is classified into three categories based on etiology: idiopathic, familial or associated.
Both familial and idiopathic PAH can be present at birth or
develop later in life. Associated PAH occurs when the disease
is secondary to other pre-existing conditions such as autoimmune disease, congenital heart and lung disease, portal
hypertension, the use of drugs similar in structure to
amphetamines and Human Immunodeficiency Virus (HIV)
infection among other conditions.I
While the pathophysiology of PAH is not fully understood, its
basic mechanisms have been identified. In patients with PAH,
there is evidence of irregular expression of potassium channels in the endothelium and smooth muscle cells in the
pulmonary artery. This irregular function can lead to an inhibited expression of the vasodilators nitric oxide and
prostacyclin. Conversely, it can also lead to the overproduction of vasoconstrictors, thromboxane A2 and endothelin-1.
These changes result in increased vasoconstriction, inflammation and thrombosis. In PAH patients, high cellular proliferation is present in the vascular wall of the pulmonary artery.2,3 This leads to increased pressure and stress on the
right ventricle of the heart; stress which, in time, can lead to
heart failure and death.
Family history is an effective tool in identifying patients who
have a higher risk of acquiring PAH.1 While no age, ethnic or
racial group is categorized as high risk, PAH does on average
affect more women than men. Additionally, PAH is more
prevalent in patients with associated conditions such as
autoimmune disease, congenital heart and lung disease, portal hypertension, HIV infection and the use of some drugs
such as fenfluramine, cocaine or amphetamines. Patients
with PAH may present with side effects similar to other heart
and lung conditions such as chest pain, dizziness, fainting,
fatigue, swelling, and shortness of breath and lightheadedness while exercising. Since signs and symptoms are
not specific to PAH, the disease may be advanced at time of
diagnosis. 4 Perfusion lung scan, echocardiogram, right heart
catheterization, electrocardiogram and chest x-rays are all
indicative in the diagnosis of PAH.

Sildenafil and General Prescribing Information
Sildenafil inhibits PDE-5 in smooth muscle of pulmonary
vasculature where PDE-5 is responsible for the degradation
of cyclic guanosine monophosphate (cGMP). Increased cGMP
concentration results in pulmonary vasculature relaxation.
This occurs when PDE-5 breaks down cGMP that forms in
response to increased nitric oxide. Increased intracellular
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cGMP inhibits calcium entry into the cell, which results in
smooth muscle relaxation. Sildenafil is available as both an
intravenous injection (IV) and an oral medication. If administering as an IV, the dose of sildenafil is 10 mg IV bolus three
times per day; if taking the oral formulation, the dose is 20
mg by mouth three times per day (four to six hours apart)
without regard to meals. The onset of action is about 60 minutes, and its duration of action is two to four hours. Sudden
cessation of sildenafil could result in an exacerbation of PAH.
There is no dose adjustment needed in renal impairment or
in hepatic impairment with Child-Pugh class A or B. This
drug is a major substrate of CYP3A4 and a minor substrate of
CYP1A2, CYP2C19, CYP2D6, and CYP2El. It is also a weak
inhibitor of CYP2C9 and CYP3A4. Therefore, dose adjustments are required when using potent CYP3A4 inhibitors,
except with erythromycin. Concomitant use of sildenafil and
itraconazole/ketoconazole is not recommended; concurrent
use with protease inhibitors and organic nitrates is contraindicated. Sildenafil should be used with caution in patients
over 65 years of age, and this drug is Pregnancy Category B.
Chronic use in children is not recommended. Patients should
avoid drinking grapefruit juice while taking this drug.s
Additionally, blood pressure and heart rate should be monitored as hypotension may develop while taking sildenafil.
Patients at increased risk of hypotension are those taking an
antihypertensive medication or those with aortic stenosis,
hypertrophic obstructive cardiomyopathy or fluid depletion.
If the patient develops pulmonary edema when taking this
drug, sildenafil should be discontinued as this could be pulmonary veno-occlusive disease. Sildenafil should be used
with caution in people taking alpha-blockers, bosentan, nitrates and other erectile dysfunction drugs. Adverse effects
such as flushing, diarrhea, myalgia and visual disturbances
may be increased with adult doses >100 mg/24 hours. Over
10 percent of patients experience a headache and dyspepsia.
Other common adverse effects are erythema, dizziness, insomnia, increased liver function tests (LFTs), urinary tract
infection and dyspnea.s
Selected Clinical Trials
Impact of First-line Sildenafil Monotreatment for Pulmonary
Arterial Hypertension, a study conducted by the Keio and
Kyorin University Hospitals, analyzed the efficacy of sildenafil as a monotreatment for PAH. Fifty-seven patients with
New York Heart Association functional class (NYHA FC) ratings of I, II, or III were enrolled; four patients dropped out of
the study due to high cost of off-label use, and seven patients
with Eisenmenger Syndrome were dismissed because of
their differing clinical characteristics from other patients
with PAH. The remaining patients were given 20 mg sildenafil three times daily as a monotreatment from January
2003 to December 2010. A 6-minute walk distance (6MWD;
an independent predictor of death in patients with PAH) and
B-type natriuretic peptide (BNP) levels were evaluated before treatment began and again during follow-up.6
It was found that the BNP tended to be lower after sildenafil
treatment, but the results were not significant. Hemodynamic parameters, however, such as the pulmonary vascular
resistance (14.6±8.7 versus 11.6± 8.6 Wood units, P<0.05),
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mean pulmonary arterial pressure (PAP: 52.1±14.0 versus
45.7±15.7 mmHg, P<0.01), mean right atrial pressure (RA:
8.0±5.5 versus 6.4±4.4 mmHg, P<0.05), and cardiac output
(CO: 3.7±1.6 versus 4.2±1.9 L/min, P<0.05), improved significantly following sildenafil treatment in the enrolled patients
as a whole. These results are indicative of sildenafil's positive
cardiovascular effects, which result in improved cardiac
function . NYHA FC either improved (n=12, 26.1 percent) or
was maintained (n=30, 65.2 percent) in 42 of 46 patients;
NYHA FC worsened in four patients (8.7 percent). Due to the
NYHA FC maintenance or improvement rate of 91.3 percent,
the study concluded that sildenafil demonstrated superior
efficacy as a monotreatment for PAH. Critiques of this study
included its lack of control group and small study population.6
Clinical Efficacy of Sildenafil in Primary Pulmonary Hypertension, a randomized, double-blind crossover study, compared the efficacy of sildenafil with placebo in patients with
primary pulmonary hypertension. Change in exercise time on
a treadmill was used as a primary endpoint. Patients were
randomized into a placebo group or sildenafil group with
doses ranging from 25 to 100 mg three times daily based on
body weight. A baseline evaluation was done before treatment began, and again after six weeks of treatment. After the
six-week evaluation, patients were crossed over to the therapy alternative to their current treatment (i.e. the sildenafil
group ceased sildenafil treatment and began the placebo
regimen, and vice versa). A final evaluation was performed
after another six weeks of treatment.7
Twenty-two patients completed the study. Exercise time
increased by 44 percent from 475 ± 168 seconds at the end
of placebo phase to 686 ± 224 seconds at the end of sildenafil
phase (p < 0.0001). It was also noted that cardiac index improved from 2.80 ± 0.9 l/m 2 to 3.45 ± 1.11/mZ (p < 0.0001).
Pulmonary artery systolic pressure decreased from 105.23 ±
17.82 mm Hg to 98.50 ± 24.38 mmHg, but these results were
found to be insignificant. Patients also reported significant
improvements in dyspnea and fatigue in a Quality of Life
questionnaire. From these results it was concluded that sildenafil significantly improves exercise tolerance, cardiac index, and quality of life in patients with primary pulmonary
hypertension. No serious side effects were noted. While
these results reflect those of other studies, the authors acknowledged that a larger study population, longer treatment
duration, and a washout period between crossover treatment would help lend credibility to these findings.7
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension, a double-blind, placebo-controlled study conducted by
the Sildenafil Use in Pulmonary Arterial Hypertension
(SUPER) Study Group, used the 6MWD test indicating a
change in exercise capacity as a primary end point of sildenafil efficacy. Placebo or sildenafil treatment (20, 40, or 80
mg) orally three times daily for 12 weeks was randomly assigned to 278 patients with PAH class II or III. Among the
265 patients who completed the study, an increase in the
6MWD was observed in all groups receiving sildenafil in
comparison to the placebo. Improvement was noted at week
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four and maintained at weeks eight and twelve. The observed treatment-related increases of 45 to 50 meters is
similar to the increases observed with other PAH medications such as intravenous epoprostenol (47 m), inhaled iloprost (36 m), and oral bosentan (44 m), and is higher than
the increase seen with the use of subcutaneous trepostinil
(16 m). There was no evidence of a dose-response relationship associated with exercise capacity. It is possible that this
is due to complete 5-PDE inhibition at the lowest dose.s
Patients receiving sildenafil treatment also experienced improvements in functional class. After twelve weeks of treatment, seven percent of patients receiving placebo noted an
improvement of at least one functional class. The proportions of FC improvements for those receiving treatment were
28 percent for those receiving 20 mg of sildenafil (P=0.003),
36 percent for those receiving 40 mg (P<0.001), and 42 percent for those receiving 80 mg (P<0.001). A significant decrease from baseline in mean pulmonary-artery pressure
and pulmonary vascular resistance was also noted in those
taking sildenafil from the placebo group. The proportion of
hospitalizations for worsening PAH was greater in the placebo group than in the combined sildenafil treatment groups
(P=0.02). 8
Adverse events experienced (such as headache, dyspepsia
and back pain) were mild to moderate in intensity for all
treatment groups.a
Two hundred seventy-seven patients were enrolled in a 12week, double-blind, randomized, placebo-controlled trial
(SUPER-1), a continuation of the original SUPER study. Two
hundred fifty-nine patients completed the study and entered
into an open-label, uncontrolled extension study (SUPER-2)
that continued until the last patient had completed three
years of sildenafil treatment. The median duration of sildenafil treatment was 1,242 days. Patients were titrated to a
dose of 80 mg of sildenafil three times daily for treatment of
PAH. As in previous studies, the 6MWD test was used as a
primary endpoint. At three years post-baseline, 127 patients
(49 percent) had an increased 6MWD. Sixty-four percent of
patients either improved or maintained their functional
class; 81 patients noted improvement, while 86 patients
maintained their current level of functioning. Treatment with
sildenafil was generally well-tolerated, and noted adverse
events were of mild to moderate severity. The study authors
acknowledged that an increased treatment duration would
be necessary to support these findings of efficacy. 9
While more thorough and lengthy studies would further validate recent findings, all current evidence suggests that sildenafil is an effective treatment for PAH. It has been shown to
significantly improve pulmonary vascular resistance, mean
pulmonary arterial pressure, mean right atrial pressure, cardiac output, exercise capacity, FC and quality of life. Sildenafil
was found to be generally well-tolerated among all patients
studied, with mild to moderate side effects:
Because most studies were aimed at assessing sildenafil's
efficacy as a monotherapy compared to placebo, more studies regarding specific dosing effectiveness would be helpful
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in determining the optimal dosage for PAH treatment. Given
current findings, however, the recommended daily dose for
PAH treatment remains at 20 mg three times daily.s There is
no evidence suggesting that sildenafil treatment has a decreased efficacy or increased adverse effects in comparison
to other PAH therapies.
Pharmaceutical Application
It is important for health care professionals, especially
pharmacists, to be knowledgeable about sildenafil and PAH.
Because sildenafil has many drug interactions and possible
adverse events associated with its use, pharmacists can play
a vital role in therapy by counseling patients when they
receive this medication. Although PAH is not a common condition, pharmacists need to be aware of PAH and to know the
signs and symptoms of PAH as well as how to treat it in order
to improve the patient's quality of life. Sildenafil can significantly improve the quality of life of a patient with PAH and
should be considered as an option for treatment in a PAH
patient. Specifically, sildenafil is one of two treatment options indicated for functional class II patients with PAH, and
one of five treatment options indicated for functional class III
patients.10
Conclusion
Pulmonary arterial hypertension is the constriction of the
pulmonary arterial lumen that can result in stress on the
right side of the heart which ultimately leads to heart failure
and death. There are only a few treatment options for PAH,
and sildenafil, a PDE-5 inhibitor, is one of the options due to
its ability to dilate the pulmonary artery. Through various
studies, sildenafil has been proven to be effective in treating
PAH as monotherapy with mild to moderate adverse events
while improving dyspnea, fatigue and quality of life. It is important for pharmacists and other health care professionals
to understand PAH as a disease state and to counsel patients
on appropriate treatment options, including sildenafil.
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